Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03416868 · ClinicalTrials.gov registry record · NA

Preliminary Study 2 to Test the Effects of Ambulatory Voice Biofeedback

A NA study of Muscle Tension Dysphonia and Vocal Fold Nodules, sponsored by Massachusetts General Hospital.

Completed
Registry status
NA
Development phase
39
Enrollment target
1
Study location

NCT03416868 is a NA study of Muscle Tension Dysphonia and Vocal Fold Nodules that has completed, run by Massachusetts General Hospital. The registered enrollment target is 39 participants, below the 285-participant average among 4 other Muscle Tension Dysphonia trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03416868, a NA study of Muscle Tension Dysphonia and Vocal Fold Nodules, has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
NA
Development phase
39 participants
Enrollment target
1
Study location

Study Summary

Patients with vocal hyperfunction will undergo standard of care voice therapy with ambulatory voice monitoring before therapy and after the first 3 voice therapy sessions. Biofeedback will be added to ambulatory monitoring after the 2nd voice therapy session only.

Interventions

  • BEHAVIORAL Ambulatory voice biofeedback

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital - Center for Laryngeal Surgery and Voice Rehabilitation - Boston

Trial Details

FieldValue
Enrollment Target 39 participants
Start Date 2018-06-01
Est. Completion 2024-02-05
Phase NA

Sponsor

Massachusetts General Hospital

2,032 total trials

What the Registry Record Tells You About NCT03416868

The ClinicalTrials.gov registry entry for NCT03416868 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 285-participant average among 4 other Muscle Tension Dysphonia trials with a reported enrollment target (86% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Muscle Tension Dysphonia appearing as the primary indexed condition, and to 1 intervention - of which Ambulatory voice biofeedback is the first listed.

NCT03416868 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT03416868 about?

NCT03416868 is a clinical study titled "Preliminary Study 2 to Test the Effects of Ambulatory Voice Biofeedback". Patients with vocal hyperfunction will undergo standard of care voice therapy with ambulatory voice monitoring before therapy and after the first 3 voice therapy sessions. Biofeedback will be added to ambulatory monitoring after the 2nd voice therapy session only.

What is the current status of trial NCT03416868?

This trial is currently completed. It is a NA study. The enrollment target is 39 participants. The study started on 2018-06-01. Estimated completion is 2024-02-05.

What conditions does trial NCT03416868 study?

This clinical trial studies the following conditions: Muscle Tension Dysphonia, Vocal Fold Nodules.

What interventions are being tested in trial NCT03416868?

The interventions under investigation include: Ambulatory voice biofeedback (BEHAVIORAL).

Who is sponsoring clinical trial NCT03416868?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03416868 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Muscle Tension Dysphonia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.